Login
Login     |     Register     |     Recover Username/Password

General Investing

Latest Acquisition Target in the Specialty Chemicals Industry: The Lubrizol Corp. (LZ)

March 23, 2011

The specialty chemicals space continues its favorable run that began in 2010, with strong end-market demand despite commodity cost headwinds. Improved portfolios and leaner balance sheets make some specialty chemicals companies ripe for acquisitions, says Credit Suisse Managing Director John McNulty.

The most recent evidence is Berkshire Hathaway’s (BRK-A) March 14 announcement to acquire The Lubrizol Corp. (LZ) for $135 per share in an all-cash transaction. The specialty chemicals company, which produces technologies for the transportation, industrial and consumer markets worldwide, will be acquired at a value of approximately $9.7 billion — one of Berkshire Hathaway‘s largest acquisitions ever — a 28% premium over Lubrizol‘s March 11 closing price.

Lubrizol gained an increase in earnings power over the past several years, benefiting from consolidation in the specialty chemicals industry, said Senior Research Analyst Dmitry Silversteyn in a June 2010 interview with The Wall Street Transcript. Silversteyn correctly forecasted a target price in the $130 range for Lubrizol, up from June 2010′s stock price in the $80-$85 range.

The analyst sees the expansive opportunities in specialty chemicals as appealing to many types of investors.

“There are investments here for every type of investor, both in terms of cap consideration as well as in terms of value, growth at reasonable price, or just outright growth. I think this is a volatile enough industry for short-term traders,” Silversteyn said in a March 2011 interview with TWST. “It also has evolving stories that will take some time to work where the market is still skeptical as to their ultimate success, which are suitable for value investors. I think if you have a theme and a style, there are stocks in my universe that would fit that.”


TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now